飞机vp加速器最新版

飞机vp加速器最新版

Quarterly Review

Very good business development at Pharmaceuticals

人类一败涂地怎么爬墙 人类一败涂地爬墙图文教学详解-游迅网:2021-1-6 · 《人类：一败涂地》中的主角那两只胳膊真的是难道了不少人，那么怎么爬墙呢？今天小编就为大家带来人类一败涂地爬墙图文教学详解，还不清楚的玩家赶紧来学习一下吧！

粘贴扭线环电线理线神器束线夹绿萝爬墙固定器自粘式线 ...:粘贴扭线环电线理线神器束线夹绿萝爬墙固定器自粘式线卡子卡扣座 宝贝属性： 固定器 自粘式 卡扣 线夹 卡子 神器 粘贴 电线 理线 原价：50.00元 折扣：4.3折 劵后价 ￥ 21.50 /包邮 领独家优惠券3.00元

Core earnings per share
€2.62 (+11.5%)
Group sales
€13.2 billion landeng破解版安卓版
Download Full Report (PDF, 0.5MB) Bayer Newsletter Investor Conference Call Share

飞机vp加速器最新版

  • Sales

    Key figure Sales (bar chart)Key figure Sales (bar chart) latern专业版破解下载Inactive key figure Sales (bar chart)

  • EBITDA Before Special Items

    Key figure EBITDA margin (bar chart)老王app安卓下载最新版 Inactive key figure EBITDA margin (bar chart)latern专业版破解下载

  • Net income

    Inactive key figure Net income (bar chart)lan 灯 破解版 Key figure Net income (bar chart)latern专业版破解下载

+9.4%

In the first quarter, sales increased by 9.4 percent on a currency- and portfolio-adjusted basis (Fx & portfolio adj.) to €13.2 billion.

View all Q1 key figures

爬墙加速器下载

Group EBITDA before special items increased by 14.9 percent to €3,893 million.

View all Q1 key figures

+37.9%

After income tax expense of €595 million (Q1 2016: €474 million) and adjusting for income from discontinued operations after income taxes and noncontrolling interest, net income for the first quarter of 2017 amounted to €2,083 million (Q1 2016: €1,511 million).

View all Q1 key figures

Business Development of the Divisions

Pharmaceuticals

Our Pharmaceuticals business expanded in all regions on a currency-adjusted basis. Sales of Pharmaceuticals rose by an encouraging 7.4 percent (Fx & portfolio adj.) to €4,263 million in the first quarter of 2017. Our key growth products once again delivered strong performance, with their combined sales rising by 20.0 percent (Fx adj.) to €1,445 million (Q1 2016: €1,187 million).

Find out more

Consumer Health

Sales of Consumer Health rose by 2.6 percent (Fx & portfolio adj.) in the first quarter of 2017 to €1,601 million. We registered encouraging growth in Europe / Middle East / Africa and Asia Pacific. Sales in North America were level year on year on a currency-adjusted basis, while business declined substantially in Latin America.

Find out more

Crop Science

In the first quarter of 2017, Crop Science posted sales of €3,120 million (Fx & portfolio adj. + 3.2 percent). Growth at Crop Protection / Seeds was largely due to encouraging performance in North America. The sales growth recorded at Environmental Science was based on the delivery of products to the company that acquired our consumer business.

Find out more

飞机vp加速器最新版